Status:
TERMINATED
The Effect of Rituximab on the Humoral Response to Influenza Vaccine
Lead Sponsor:
Tel-Aviv Sourasky Medical Center
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18-85 years
Phase:
NA
Brief Summary
Rituximab is a genetically engineered chimeric anti-CD20 monoclonal antibody that selectively targets CD20+ B cells and induces a transient depletion of the CD20+ mature B cell subpopulation.The objec...
Detailed Description
The study population comprised RA patients treated with conventional disease modifying drugs with or without rituximab. Split-virion inactivated vaccine containing 15 mcg hemagglutinin/dose of B/Shang...
Eligibility Criteria
Inclusion
- Patients with Rheumatoid Arthritis
- Age-18-85
- Treatment with Rituximab and other Disease modifying drugs
Exclusion
- Treatment with anti TNF alpha
- Allergy to eggs
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
End Date :
February 1 2006
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT00466037
Start Date
September 1 2005
End Date
February 1 2006
Last Update
April 27 2007
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.